2013-02-26 01:48:58 - Recently published research from GlobalData, "PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022", is now available at Fast Market Research

GlobalData has released its new Country report, "PharmaPoint: HIV - Japan Drug Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose

combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.


Full Report Details at
- www.fastmr.com/prod/544175_pharmapoint_hiv_japan_drug_forecast_a ..


This can be explained by the low prevalence and incidence rates of HIV in Japan. The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. GlobalData believes that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market.

Scope

* Overview of Japan including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Japan from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Japan HIV market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for HIV
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Japan

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
3.2.1 Primary or Acute Infection
3.2.2 Chronic Infection
3.2.3 Advanced Infection/AIDS
4 Disease Management
4.1 Treatment Overview
4.2 Japan
4.2.1 Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
5.3.1 Atripla (efavirenz/emtricitabine/tenofovir)
5.3.2 Complera (emtricitabine/tenofovir/rilpivirine)
5.3.3 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine)
5.3.4 Truvada (tenofovir disoproxil fumarate/emtricitabine)
5.3.5 Epzicom (abacavir/lamivudine)
5.3.6 Kaletra (lopinavir/ritonavir)
5.3.7 Reyataz (atazanavir)
5.3.8 Prezista (darunavir)
5.3.9 Norvir (ritonavir)
5.3.10 Isentress (raltegravir)
5.3.11 Entry inhibitors
6 Opportunity and Unmet Need
6.1 Overview
6.1.1 Simplified regimens and dosing frequency
6.1.2 Side effects and toxicities
6.1.3 Drug resistance
6.1.4 Prophylaxis
6.1.5 Lack of functional cure
6.1.6 Patient awareness
6.1.7 Treatment availability
6.1.8 Treatment affordability
6.2 Unmet Needs Gap Analysis
6.3 Opportunities
6.3.1 Development of treatments to counter drug resistance
6.3.2 Collaborations to develop newer STRs
6.3.3 Development of new injectable formulations
6.3.4 Development of new prophylactics
6.3.5 Development of drugs that use a novel mechanism of action
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cobicistat
7.2.2 Elvitegravir
7.2.3 Dolutegravir
7.2.4 572-Trii
7.2.5 Quad 2
8 Market Outlook
8.1 Japan
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 HIV Prevalence
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=544175&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.